Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

A man developed skin issues from cancer medication, which improved with specific treatments.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

Stopping mitochondrial respiration can prevent brain cancer spread in skin cancer patients, and plant compound β-sitosterol could help achieve this.

Sonidegib and vismodegib have different side effects and reporting patterns.

Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.

A substance called Compound 2g can strongly block STS (a hormone-related enzyme) without affecting estrogen levels, making it potentially good for treating breast cancer.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Ruxolitinib can help regrow hair in severe alopecia areata.

A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Nephronectin is linked to worse breast cancer outcomes and helps cancer spread.

Baricitinib significantly regrows hair in severe alopecia areata patients.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Trametinib can cause skin issues, but they can often be managed without stopping the drug.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.